GERMANTOWN, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Orgenesis (ORGS), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), continues to grow the ...

Expansion Adds U.S. FDA and EU Annex 1 Compliant GMP Capacity with High-Throughput Manufacturing Design and Advanced Automation by Q3 2026. "As more therapies advance to late-stage development, the ...

Syena secures exclusive license to Miltenyi Biotec’s PRAME TCR Syena, co-founded by Replay and MD Anderson in 2023, will develop an off-the-shelf PRAME TCR-NK cell therapy, with IND anticipated Q1 ...

SEATTLE--(BUSINESS WIRE)--Pluristyx, a leading provider of Good Manufacturing Practices (GMP), cutting-edge, induced pluripotent stem cell (iPSC) technologies, today announced the immediate ...

The first GMP cell therapy product ever manufactured for clinical use on the Cell Shuttle™ and released using Cell Q™, is expected to be infused into patients within Cabaletta’s RESET™ clinical trial ...

A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising ...

Buffalo, N.Y.-based Roswell Park Comprehensive Cancer Center recently opened the Roswell Park GMP Engineering & Cell Manufacturing Facility, a $98 million cell and gene therapy hub aimed at growing ...

Cell and gene therapies use the body's building blocks - cells and genetic material - to boost the immune system or correct ...